AR056216A1 - Derivados de piridopirazina y su uso - Google Patents

Derivados de piridopirazina y su uso

Info

Publication number
AR056216A1
AR056216A1 ARP060104948A ARP060104948A AR056216A1 AR 056216 A1 AR056216 A1 AR 056216A1 AR P060104948 A ARP060104948 A AR P060104948A AR P060104948 A ARP060104948 A AR P060104948A AR 056216 A1 AR056216 A1 AR 056216A1
Authority
AR
Argentina
Prior art keywords
alkyl
aryl
heteroaryl
cycloalkyl
heterocyclyl
Prior art date
Application number
ARP060104948A
Other languages
English (en)
Inventor
Irene Seipelt
Eckhard Claus
Tilmann Schuster
Michael Czech
Emmanuel Polymeropoulos
Eckhard Guenther
Original Assignee
Zentaris Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Ag filed Critical Zentaris Ag
Publication of AR056216A1 publication Critical patent/AR056216A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)

Abstract

La presente pone a disposicion compuestos de piridopirazina, que son apropiados para el tratamiento o la prevencion de estados fisiologicos y/o patofisiologicos en mamíferos mediados y/o modulados por vías de transduccion de senales y/o enzimas, en especial en el ser humano. Reivindicacion 1: Uso de un compuesto de acuerdo con la formula general (1) en donde los sustituyentes R1, R2, R3, R4 tienen el siguiente significado: R1 y R2 pueden ser, de modo independiente entre sí: (i) hidrogeno, (ii) hidroxilo, (iii) halogeno, (iv) alquilo, en donde el radical alquilo está saturado y puede estar compuesto de 1 a 8 átomos de C, (v) arilo no sustituido o sustituido, en donde el radical arilo puede estar mono- o polisustituido con F, Cl, Br, I, CF3, CN, NH2, NH-alquilo, NH-cicloalquilo, NH-heterociclilo, NH-arilo, NH-heteroarilo, NH-alquil-cicloalquilo, NH-alquil-heterociclilo, NH-alquil-arilo, NH-alquil-heteroarilo, NH-alquil-NH2, NH-alquil-OH, N(alquilo)2, NHC(O)-alquilo, NHC(O)- cicloalquilo, NHC(O)-heterociclilo, NHC(O)-arilo, NHC(O)-heteroarilo, NHC(O)-alquil-arilo, NHC(O)-alquilheteroarilo, NHSO2-alquilo, NHSO2-cicloalquilo, NHSO2-heterociclilo, NHSO2-arilo, NHSO2-heteroarilo, NHSO2-alquil-arilo, NHSO2-alquil- heteroarilo, NO2, SH, S-alquilo, S-arilo, S-heteroarilo, OH, OCF3, O-alquilo, O-cicloalquilo, O-heterociclilo, O-arilo, O-heteroarilo, O-alquil-cicloalquilo, O-alquil-heterociclilo, O-alquilarilo, O-alquilheteroarilo, O-alquil-OH, O-(CH2)n-O, OC(O)- alquilo, OC(O)-cicloalquilo, OC(O)-heterociclilo, OC(O)-arilo, OC(O)-heteroarilo, OC(O)-alquilarilo, OC(O)-alquil-heteroarilo, OSO3H, OSO2-alquilo, OSO2-cicloalquilo, OSO2-heterociclilo, OSO2-arilo, OSO2-heteroarilo, OSO2-alquil-arilo, OSO2-alquil- heteroarilo, OP(O)(OH)2, C(O)-alquilo, C(O)-arilo, C(O)-heteroarilo, CO2H, CO2-alquilo, CO2-cicloalquilo, CO2-heterociclilo, CO2-arilo, CO2-heteroarilo, CO2-alquil-cicloalquilo, CO2-alquil-heterociclilo, CO2-alquil-arilo, CO2-alquil-heteroarilo, C(O)-NH2, C(O)NH-alquilo, C(O)NH-cicloalquilo, C(O)NH-heterociclilo, C(O)NH-arilo, C(O)NH-heteroarilo, C(O)NH-alquil-cicloalquilo, C(O)NH-alquil-heterociclilo, C(O)NH-alquil-heteroarilo, C(O)N(alquilo)2, C(O)N(cicloalquilo)2, C(O)N(heteroarilo)2, C(O)N(arilo)2, SO-alquilo, SO-arilo, SO2-alquilo, SO2-arilo, SO2NH2, SO2NH-alquilo, SO2NH-arilo, SO2NH-heteroarilo, SO2NH-alquil-arilo, SO3H, SO2O-alquilo, SO2O-arilo, SO2O-alquil-arilo, alquilo, cicloalquilo, heterociclilo, arilo o heteroarilo, igual o diferente, n puede adoptar el valor 1, 2 o 3, y los sustituyentes de alquilo, cicloalquilo, heterociclilo, arilo, heteroarilo, alquil-cicloalquilo, alquil-heterociclilo, alquil-arilo y alquil-heteroarilo pueden estar, a su vez, sustituidos, (vi) heteroarilo no sustituido o sustituido, en donde el radical heteroarilo puede estar mono- o polisustituido con F, Cl, Br, I, CF3, CN, NH2, NH-alquilo, NH-cicloalquilo, NH-heterociclilo, NH-arilo, NH-heteroarilo, NH-alquil-cicloalquilo, NH- alquil-heterociclilo, NH-alquil-arilo, NH-alquil-heteroarilo, NH-alquil-NH2, NH-alquil-OH, N(alquilo)2, NHC(O)-alquilo, NHC(O)-cicloalquilo, NHC(O)-heterociclilo, NHC(O)-arilo, NHC(O)-heteroarilo, NHC(O)-alquil-arilo, NHC(O)-alquil-heteroarilo, NHSO2-alquilo, NHSO2-cicloalquilo, NHSO2-heterociclilo, NHSO2-arilo, NHSO2-heteroarilo, NHSO2-alquil-arilo, NHSO2-alquil-heteroarilo, NO2, SH, S-alquilo, S-arilo, S-heteroarilo, OH, OCF3, O-alquilo, O-cicloalquilo, O-arilo, O-heteroarilo, O-alquil- cicloalquilo, O-alquil-heterociclilo, O-alquil-arilo, O-alquil-heteroarilo, OC(O)-alquilo, OC(O)-cicloalquilo, OC(O)-heterociclilo, OC(O)-arilo, OC(O)-heteroarilo, OC(O)-alquil-heteroarilo, OSO3H, OSO2-alquilo, OSO2-cicloalquilo, OSO2-heterociclilo, OSO2-arilo, OSO2-heteroarilo, OSO2-alquil-arilo, OSO2-alquil-heteroarilo, OP(O)(OH)2, C(O)-alquilo, C(O)-arilo, C(O)-heteroarilo, CO2H, CO2-alquilo, CO2-cicloalquilo, CO2-heterociclilo, CO2-arilo, CO2-heteroarilo, CO2-alquil-cicloalquilo, CO2-alquil- heterociclilo, CO2-alquil-arilo, CO2-alquil-heteroarilo, C(O)-NH2, C(O)NH-alquilo, C(O)NH-cicloalquilo, C(O)NH-heterociclilo, C(O)NH-arilo, C(O)NH-heteroarilo, C(O)NH-alquil-cicloalquilo, C(O)NH-alquil-heterociclilo, C(O)NH-alquil-arilo, C(O)NH- alquil-heteroarilo, C(O)N(alquilo)2, C(O)N(cicloalquilo)2, C(O)N(arilo)2, C(O)N(heteroarilo)2, SO2NH2, SO2NH-alquilo, SO2NH-arilo, SO2NH-heteroarilo, SO2NH-alquil-arilo, SO3H, SO2O-alquilo, SO2O-arilo, SO2O-alquil-arilo, alquilo, cicloalquilo, heterociclilo, arilo o heteroarilo, igual o diferente, y los sustituyentes de alquilo, cicloalquilo, heterociclilo, arilo y heteroarilo pueden estar, a su vez, sustituidos, (vii) OR5, en donde R5 puede ser alquilo, cicloalquilo, heterociclilo, arilo, heteroarilo, alquilcicloalquilo, alquil-heterociclilo, alquil-arilo o alquil-heteroarilo, y los sustituyentes de alquilo, cicloalquilo, heterociclilo, arilo, heteroarilo, alquil-cicloalquilo, alquil-heterociclilo, alquilarilo o alquil- heteroarilo pueden estar, a su vez, sustituidos, (viii) SR6, en donde R6 puede ser alquilo, cicloalquilo, heterociclilo, arilo, heteroarilo, alquil-cicloalquilo, alquil-heterociclilo, alquil-arilo o alquil-heteroarilo, y los sustituyentes de alquilo, cicloalquilo, heterociclilo, arilo y heteroarilo, alquil-cicloalquilo, alquil-heterociclilo, alquil-arilo, alquil-heteroarilo pueden estar, a su vez, sustituidos, (ix) NR7R8, en donde R7 y R8 pueden ser, de modo independiente entre sí, hidrogeno, alquilo, cicloalquilo, heterociclilo, arilo, heteroarilo, alquil-cicloalquilo, alquil-heterociclilo, alquil-arilo o alquil-heteroarilo, y los sustituyentes de alquilo, cicloalquilo, heterociclilo, arilo y heteroarilo, alquil-cicloalquilo, alquil heterociclilo alquil-arilo o alquil-heteroarilo pueden estar, a su vez, sustituidos, o R7 y R8 son juntos cicloalquilo o heterociclilo, en donde cicloalquilo y heterociclilo pueden estar, a su vez, sustituidos; R3 y R4 pueden ser, de modo independiente entre sí, hidrogeno o NR9R10, con la condicion de que, cuando R3 = NR9R10, R4 = H, y cuando R4 = NR9R10, R3 = H, en donde R9 puede ser hidrogeno, alquilo, cicloalquilo, heterociclilo, arilo, heteroarilo, alquil-cicloalquilo, alquil- heterociclilo, alquil-arilo o alquil-heteroarilo, y los sustituyentes de alquilo, cicloalquilo, heterociclilo, arilo y heteroarilo, alquil-cicloalquilo, alquil heterociclilo alquil-arilo o alquil-heteroarilo pueden estar, a su vez, sustituidos, y R10 puede ser a) -C(Y)NR11R12, en donde Y = O, S y R11 y R12 son, de modo independiente entre sí, (i) hidrogeno, (ii) alquilo no sustituido o sustituido, en donde el radical alquilo puede estar mono- o polisustituido con F, Cl, Br, I, CF3, CN, NH2, NH-alquilo, NH-cicloalquilo, NH-heterociclilo, NH-arilo, NH-heteroarilo, NH-alquil-cicloalquilo, NH-alquil-heterociclilo, NH-alquil-arilo, NH-alquil-heteroarilo, N(alquilo)2, NHC(O)-alquilo, NHC(O)-cicloalquilo, NHC(O)-heterociclilo, NHC(O)-arilo, NHC(O)-heteroarilo, NHC(O)-alquil-arilo, NHC(O)-alquil-heteroarilo, NHSO2-alquilo, NHSO2-cicloalquilo, NHSO2-heterociclilo, NHSO2-arilo, NHSO2-heteroarilo, NHSO2-alquil-arilo, NHSO2-alquil-heteroarilo, NO2, SH, S-alquilo, S-cicloalquilo, S- heterociclilo, S-arilo, S-heteroarilo, OH, OCF3, O-alquilo, O-cicloalquilo, O-heterociclilo, O-arilo, O-heteroarilo, O-alquil-cicloalquilo, O-alquil-heterociclilo, O-alquilarilo, O-alquilheteroarilo, OC(O)-alquilo, OC(O)-cicloalquilo, OC(O)- heterociclilo, OC(O)-arilo, OC(O)-heteroarilo, OC(O)-alquil-arilo, OC(O)-alquil-heteroarilo, OSO3H, OSO2-alquilo, OSO2-cicloalquilo, OSO2-heterociclilo, OSO2-arilo, OSO2-heteroarilo, OSO2-alquil-arilo, OSO2-alquil-heteroarilo, OP(O)(OH)2, C(O)- alquilo, C(O)-arilo, C(O)-heteroarilo, CO2H, CO2-alquilo, CO2-cicloalquilo, CO2-heterociclilo, CO2-arilo, CO2-heteroarilo, CO2-alquil-cicloalquilo, CO2-alquil-heterociclilo, CO2-alquil-arilo, CO2-alquil-heteroarilo, C(O)-NH2, C(O)NH-alquilo, C(O)NH- cicloalquilo, C(O)NH-heterociclilo, C(O)NH-arilo, C(O)NH-heteroarilo, C(O)NH-alquil-cicloalquilo, C(O)NH-alquil-heterociclilo, C(O)NH-alquil-arilo, C(O)NH-alquil-heteroarilo, C(O)N(alquilo)2, C(O)N(cicloalquilo)2, C(O)N(heteroarilo)2, C(O)N(arilo)2, SO-alquilo, SO-arilo, SO2-alquilo, SO2-arilo, SO2NH2, SO2NH-alquilo, SO2NH-arilo, SO2NH-heteroarilo, SO2NH-alquil-arilo, SO3H, SO2O-alquilo, SO2O-arilo, SO2O-alquil-arilo, cicloalquilo, heterociclilo, arilo o heteroarilo, igual o diferente, (iii) cicloalquilo no sustituido o sustituido, en donde el radical cicloalquilo puede estar mono- o polisustituido con F, Cl, Br, I, NH2, NH-alquilo, NH-cicloalquilo, NH-heterociclilo, NH-arilo, NH-heteroarilo, NH-alquil-arilo, NH-alquil-heteroarilo, N(alquilo)2, NHC(O)-alquilo, NHC(O)-cicloalquilo, NHC(O)-heterociclilo, NHC(O)-arilo, NHC(O)-heteroarilo, NHC(O)-alquil-arilo, NHC(O)-alquil-heteroarilo, NHSO2-alquilo, NHSO2-cicloalquilo, NHSO2-heterociclilo, NHSO2-arilo, NHSO2-heteroarilo, NHSO2- alquil-arilo, NHSO2-alquil-heteroarilo, OH, O-alquilo, O-cicloalquilo, O-heterociclilo, O-arilo, O-heteroarilo, O-alquilarilo, O-alquilheteroarilo, OC(O)-alquilo, OC(O)-cicloalquilo, OC(O)-heterociclilo, OC(O)-arilo, OC(O)-heteroarilo, OC(O)-alquil- arilo, OC(O)-alquil-heteroarilo, OSO3H, OSO2-alquilo, OSO2-cicloalquilo, OSO2-heterociclilo, OSO2-arilo, OSO2-heteroarilo, OSO2-alquil-arilo, OSO2-alquil-heteroarilo, OP(O)(OH)2, CO2H, CO2-alquilo, CO2-cicloalquilo, CO2-heterociclilo, CO2-arilo, CO2- heteroarilo, CO2-alquil-cicloalquilo, CO2-alquil-heterociclilo, CO2-alquil-arilo, CO2-alquil-heteroarilo, C(O)-NH2, C(O)NH-alquilo, C(O)NH-cicloalquilo, C(O)NH-heterociclilo, C(O)NH-arilo, C(O)NH-heteroarilo, C(O)NH-alquil-cicloalquilo, C(O)NH- alquil-heterociclilo, C(O)NH-alquil-arilo, C(O)NH-alquil-heteroarilo, C(O)N(alquilo)2, C(O)N(cicloalquilo)2, C(O)N(heteroarilo)2, C(O)N(arilo)2, alquilo o arilo, igual o diferente, (iv) heterociclilo no sustituido o sustituido, en donde el radical heterociclilo puede estar mono- o polisustituido con OH, O-alquilo, O-arilo, NH2, NH-alquilo, NH-arilo, alquilo, alquil-arilo, o aril
ARP060104948A 2005-11-11 2006-11-13 Derivados de piridopirazina y su uso AR056216A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73570705P 2005-11-11 2005-11-11
EP05024692A EP1790342A1 (de) 2005-11-11 2005-11-11 Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege

Publications (1)

Publication Number Publication Date
AR056216A1 true AR056216A1 (es) 2007-09-26

Family

ID=36424666

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104948A AR056216A1 (es) 2005-11-11 2006-11-13 Derivados de piridopirazina y su uso

Country Status (21)

Country Link
US (1) US8937068B2 (es)
EP (2) EP1790342A1 (es)
JP (1) JP5448450B2 (es)
KR (1) KR101473662B1 (es)
CN (1) CN101330918B (es)
AR (1) AR056216A1 (es)
AU (1) AU2006334721B2 (es)
BR (1) BRPI0618451A2 (es)
CA (1) CA2628186A1 (es)
ES (1) ES2543962T3 (es)
HK (1) HK1125823A1 (es)
IL (1) IL191160A (es)
NO (1) NO20082509L (es)
NZ (1) NZ595879A (es)
PL (1) PL1962854T3 (es)
RU (1) RU2487713C2 (es)
SG (1) SG10201401061XA (es)
TW (1) TWI423973B (es)
UA (1) UA95464C2 (es)
WO (1) WO2007079999A2 (es)
ZA (1) ZA200803867B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090118139A1 (en) * 2000-11-07 2009-05-07 Caliper Life Sciences, Inc. Microfluidic method and system for enzyme inhibition activity screening
WO2007054556A1 (de) * 2005-11-11 2007-05-18 Æterna Zentaris Gmbh Neue pyridopyrazine und deren verwendung als modulatoren von kinasen
US9139630B2 (en) 2006-07-11 2015-09-22 Rutgers, The State University Of New Jersey Compositions and methods for preparing recombinant MG53 and methods for optimizing same
US9458465B2 (en) * 2007-12-04 2016-10-04 Rutgers, The State University Of New Jersey Compositions and methods to modulate cell membrane resealing
US7893066B2 (en) * 2006-10-05 2011-02-22 Gilead Palo Alto, Inc. Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors
EP1990342A1 (en) * 2007-05-10 2008-11-12 AEterna Zentaris GmbH Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof
US8399483B2 (en) 2007-12-21 2013-03-19 Ucb Pharma S.A. Quinoxaline and quinoline derivatives as kinase inhibitors
WO2010045374A1 (en) * 2008-10-15 2010-04-22 Gilead Palo Alto, Inc. 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors
WO2010052448A2 (en) * 2008-11-05 2010-05-14 Ucb Pharma S.A. Fused pyrazine derivatives as kinase inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
US20130123340A1 (en) * 2010-05-11 2013-05-16 Peking University, Office Of Technology Transfer Compositions and methods for the treatment and prevention of cardiac ischemic injury
EP2635908B1 (en) 2010-11-05 2015-08-19 University of Medicine and Dentistry of New Jersey Serum mg53 as a diagnostic marker for tissue injury
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
EP2508184A1 (en) 2011-04-06 2012-10-10 Æterna Zentaris GmbH Pyridopyrazine derivatives and their use
WO2013018733A1 (ja) 2011-07-29 2013-02-07 富士フイルム株式会社 １，５－ナフチリジン誘導体又はその塩
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
EP2944637B1 (en) * 2013-01-11 2020-02-19 FUJIFILM Corporation Nitrogen-containing heterocylic compound or salt thereof
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
WO2015144804A1 (en) 2014-03-26 2015-10-01 Astex Therapeutics Ltd Combinations
CA2943687C (en) 2014-03-26 2024-02-13 Astex Therapeutics Ltd Combinations of an fgfr inhibitor and an igf1r inhibitor
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
WO2016203335A1 (en) * 2015-06-18 2016-12-22 Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
JP6898919B2 (ja) 2015-09-23 2021-07-07 ヤンセン ファーマシューティカ エヌ．ベー． 新規化合物
CN108137546B (zh) 2015-09-23 2021-07-27 詹森药业有限公司 双杂芳基取代的1,4-苯并二氮杂卓化合物及其用于治疗癌症的用途
CN107619388A (zh) * 2016-07-13 2018-01-23 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
US11117894B2 (en) 2017-06-22 2021-09-14 City Of Hope Pyridopyrazine compounds and uses thereof
US20210238605A1 (en) * 2018-06-15 2021-08-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of pi3kc2b inhibitors for the preservation of vascular endothelial cell barrier integrity
CN111892597B (zh) * 2020-09-01 2023-07-25 山西天宏达安医药科技有限公司 一种喹喔啉基吡啶并吡嗪类化合物及其制备方法与应用

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3209004A (en) 1963-05-17 1965-09-28 American Home Prod 3, 6-diamino-n-(2, 2-dialkoxyethyl) pyrido[2, 3-b] pyrazine-2-carboxamides
US3180868A (en) 1963-07-24 1965-04-27 American Home Prod 3, 6-diamino-n-(substituted)pyrido[2, 3-b]-pyrazine-2-carboxamides
US3809695A (en) 1967-04-19 1974-05-07 Degussa 2,6-dichloro-3-nitro-pyridine
JPS5053394A (es) 1973-09-20 1975-05-12
US4082845A (en) 1977-04-25 1978-04-04 Merck & Co., Inc. 3-(1-Piperazinyl)-pyrido[2,3-b]pyrazines
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
CA2172750A1 (en) 1995-03-28 1996-09-29 Shinzo Seko Process for producing aminonitropyridines
UA71555C2 (en) 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
CA2315720A1 (en) 1997-12-22 1999-07-01 Bayer Corporation Inhibition of p38 kinase activity using substituted heterocyclic ureas
AU2879799A (en) 1998-02-26 1999-09-15 Neurogen Corporation 4-(4-piperidylmethylamino) substituted heteroaryl fused pyridines: gaba brain receptor ligands
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
KR20010101203A (ko) 1998-12-15 2001-11-14 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Ｍｅｋ 저해제의 이식 조직 거부를 예방하기 위한 용도
YU45401A (sh) 1998-12-22 2004-07-15 Warner-Lambert Company Antikancerogena kombinacija
KR100785363B1 (ko) 2000-04-25 2007-12-18 이코스 코포레이션 인간 포스파티딜-이노시톨 3-키나제 델타의 억제제
YU2503A (sh) 2000-07-19 2006-05-25 Warner-Lambert Company Oksigenovani estri 4-jodo fenilamino benzhidroksamskih kiselina
EP1326610B1 (en) 2000-10-12 2006-11-15 Merck & Co., Inc. Aza-and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
US7432270B2 (en) 2001-05-05 2008-10-07 Smithkline Beecham P.L.C. N-aroyl cyclic amines
MXPA04002397A (es) 2001-09-14 2004-12-02 Methylgene Inc Inhibidores de histona deacetilasa.
TW200406410A (en) 2002-01-29 2004-05-01 Glaxo Group Ltd Compounds
AU2003239302A1 (en) 2002-01-29 2003-09-02 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
WO2003068223A1 (en) 2002-02-11 2003-08-21 Bayer Corporation Aryl ureas with raf kinase and angiogenesis inhibiting activity
CA2480800C (en) 2002-04-08 2008-09-23 Mark T. Bilodeau Inhibitors of akt activity
US20060142178A1 (en) 2002-04-08 2006-06-29 Barnett Stanley F Method of treating cancer
WO2003086403A1 (en) 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
JP4903997B2 (ja) 2002-07-02 2012-03-28 サザン リサーチ インスティチュート ＦｔｓＺの阻害剤およびそれらの用途
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
CA2500727A1 (en) 2002-10-03 2004-04-15 Targegen, Inc. Vasculostatic agents and methods of use thereof
US20040102360A1 (en) * 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
US20040092521A1 (en) 2002-11-12 2004-05-13 Altenbach Robert J. Bicyclic-substituted amines as histamine-3 receptor ligands
AR042461A1 (es) 2002-12-13 2005-06-22 Neurogen Corp Analogos 2-sustituidos de quinazolin-4-il - amina. composiciones farmaceuticas
DE10323345A1 (de) * 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
CA2524525C (en) * 2003-05-23 2012-01-03 Zentaris Gmbh Novel pyridopyrazines and use thereof as kinase modulators
KR101132599B1 (ko) 2003-06-05 2012-06-21 아에테르나 젠타리스 게엠베하 아폽토시스 유도 효과를 갖는 인돌 유도체
WO2005007099A2 (en) * 2003-07-10 2005-01-27 Imclone Systems Incorporated Pkb inhibitors as anti-tumor agents
SE0302304D0 (sv) 2003-08-27 2003-08-27 Astrazeneca Ab Novel compounds
WO2005023771A1 (ja) 2003-09-05 2005-03-17 Ono Pharmaceutical Co., Ltd. ケモカインレセプターアンタゴニストおよびその医薬用途
AU2004270740A1 (en) 2003-09-09 2005-03-17 Neurogen Corporation 4 - heterobicyclyamino - substituted quinazolines and analogues therof as capsaicin - antagonists
AU2004297235A1 (en) 2003-12-04 2005-06-23 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
WO2005061519A1 (en) 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
US20050165028A1 (en) 2004-01-23 2005-07-28 Norman Mark H. Vanilloid receptor ligands and their use in treatments
DE102004017932A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US20050256118A1 (en) 2004-05-12 2005-11-17 Altenbach Robert J Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US7098222B2 (en) 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US7205316B2 (en) 2004-05-12 2007-04-17 Abbott Laboratories Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
US20050256309A1 (en) 2004-05-12 2005-11-17 Altenbach Robert J Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands
EP1796466A4 (en) 2004-06-15 2009-09-02 Glaxo Group Ltd ANTIBACTERIAL AGENTS
GB0413955D0 (en) 2004-06-22 2004-07-28 Syngenta Participations Ag Chemical compounds
GB0413953D0 (en) 2004-06-22 2004-07-28 Syngenta Participations Ag Chemical compounds
WO2006014580A1 (en) 2004-07-08 2006-02-09 Glaxo Group Limited Antibacterial agents
US7648984B2 (en) 2004-07-13 2010-01-19 Glaxo Group Limited Antibacterial agents
US20070270417A1 (en) 2004-07-22 2007-11-22 Glaxo Group Limited Antibacterial Agents
EP1781669B1 (en) 2004-08-02 2010-10-13 Glaxo Group Limited Antibacterial agents
WO2006020561A2 (en) 2004-08-09 2006-02-23 Glaxo Group Limited Antibacterial agents
DE102004041163A1 (de) 2004-08-25 2006-03-02 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
EP1786812B1 (en) 2004-09-03 2011-11-09 Merck Serono SA Pyridine methylene azolidinones and their use as phosphoinositide inhibitors
JP2006137723A (ja) 2004-11-15 2006-06-01 Kyowa Hakko Kogyo Co Ltd スルホンアミド誘導体
US20090137558A1 (en) 2004-12-03 2009-05-28 Peakdale Molecular Limited Pyridine based compounds useful as intermediates for pharmaceutical or agricultural end-products
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
JP2008528598A (ja) 2005-01-25 2008-07-31 グラクソ グループ リミテッド 抗菌剤
JP2008528587A (ja) 2005-01-25 2008-07-31 グラクソ グループ リミテッド 抗菌剤
JP2008528588A (ja) 2005-01-25 2008-07-31 グラクソ グループ リミテッド 抗菌剤
JP2008528586A (ja) 2005-01-25 2008-07-31 グラクソ グループ リミテッド 抗菌剤
JP2008530111A (ja) 2005-02-14 2008-08-07 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性の阻害剤
US20070032493A1 (en) 2005-05-26 2007-02-08 Synta Pharmaceuticals Corp. Method for treating B cell regulated autoimmune disorders
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
NZ565749A (en) 2005-08-26 2010-12-24 Serono Lab Pyrazine derivatives and use as PI3K inhibitors
KR101396783B1 (ko) 2005-10-07 2014-05-21 엑셀리시스, 인코포레이티드 포스파티딜이노시톨 3-키나아제 억제제 및 이의 사용 방법
WO2007054556A1 (de) 2005-11-11 2007-05-18 Æterna Zentaris Gmbh Neue pyridopyrazine und deren verwendung als modulatoren von kinasen

Also Published As

Publication number Publication date
JP5448450B2 (ja) 2014-03-19
NO20082509L (no) 2008-07-23
CA2628186A1 (en) 2007-07-19
HK1125823A1 (zh) 2009-08-21
AU2006334721B2 (en) 2011-08-11
RU2008123219A (ru) 2009-12-20
CN101330918B (zh) 2015-09-02
WO2007079999A3 (de) 2007-10-04
EP1962854A2 (de) 2008-09-03
TW200736253A (en) 2007-10-01
EP1962854B1 (de) 2015-05-06
EP1790342A1 (de) 2007-05-30
JP2009515854A (ja) 2009-04-16
NZ595879A (en) 2013-07-26
UA95464C2 (en) 2011-08-10
ZA200803867B (en) 2009-05-27
BRPI0618451A2 (pt) 2011-08-30
CN101330918A (zh) 2008-12-24
US20070123494A1 (en) 2007-05-31
AU2006334721A1 (en) 2007-07-19
SG10201401061XA (en) 2014-07-30
US8937068B2 (en) 2015-01-20
RU2487713C2 (ru) 2013-07-20
IL191160A0 (en) 2008-12-29
WO2007079999A2 (de) 2007-07-19
KR20080068116A (ko) 2008-07-22
PL1962854T3 (pl) 2015-10-30
TWI423973B (zh) 2014-01-21
IL191160A (en) 2016-03-31
KR101473662B1 (ko) 2014-12-17
ES2543962T3 (es) 2015-08-26

Similar Documents

Publication Publication Date Title
AR056216A1 (es) Derivados de piridopirazina y su uso
AR045686A1 (es) Derivados de pirido[2,3-b]pirazinas, y su uso como moduladores de quinasas
AR085844A1 (es) Derivados de piridopirazina y sus usos
AR045685A1 (es) Piridopirazinas, procedimiento para prepararlas y su uso como inhibidores de quinasas
MY198016A (en) Flame retardant mixtures, flame-retardant polymer compositions, cables endowed therewith and use thereof
AR036098A1 (es) Derivados de 1-oxa-2,8-diaza-espiro[4.5]dec-2-eno sustituidos, procedimientos para su preparacion, su uso para la preparacion de medicamentos y medicamentos que contienen estos compuestos
AP1587A (en) Azaindoles.
RU2015135621A (ru) Композиция, ускоряющая отверждение
RU2007123025A (ru) Способ предсказуемого окрашивания кератиновых волокон нанесением композиции, содержащей производное диамино-n, n-дигидропиразолона, и основной композиции или композиции с золотистым отливом
ES2621407T3 (es) Ciclohexildiaminas sustituidas
RU2008139192A (ru) N-формилгидроксиламины
AR039689A1 (es) Difenilazetidinonas sustituidas, medicamentos que comprenden estos compuestos y su uso
GT200600164A (es) Derivados de dihidrobenzofuranos y usos de los mismos
AR075935A1 (es) Derivados de quinoxalina y su uso para el tratamiento de tumores benignos y malignos
TW200621768A (en) Aminopiperidine derivatives, preparation thereof and therapeutic use thereof
BR112015004802B1 (pt) Usos de uma composição
ES2188556T3 (es) Complejos metalicos de poliaminoacidos biciclicos, su procedimiento de preparacion y su aplicacion en formacion de imagenes medicas.
ES2200214T3 (es) Mezclas reticulables y un procedimiento para su preparacion.
AR011689A1 (es) Metodo para lavar un articulo de tela colorido con proteccion del color de la tela y/o retencion de la fragancia del medio de lavado.
ATE513882T1 (de) Farbstoffmischungen
DE59207397D1 (de) Neue Erucyl-, Brassidyl- und Nervonylderivate
ES2124261T3 (es) 4-(1-hidroxi-, 1-aciloxi-, o 1-carbamoiloxi)-5-hidroxi-2(5h)-furanonas 2- y 5-alquil y fenil sustituidas como agentes antiinflamatorios.
KR970065650A (ko) 1, 4-디케토피롤로피롤 및 퀴나크리돈의 3성분 고용체
TR200200360T2 (tr) Antibakteriyel aktif maddeler.
ES2232386T3 (es) Ignifugo, composicion retardadora de la produccion de llama y articulos moldeados de esta.

Legal Events

Date Code Title Description
FB Suspension of granting procedure